Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Opus Genetics ( (IRD) ) is now available.
Opus Genetics, a gene therapy developer targeting rare inherited retinal diseases with a diversified AAV-based pipeline spanning seven indications and two clinical-stage programs, is positioning itself as a focused player in the IRD space with a portfolio strategy designed to generate multiple clinical milestones and capital-efficient development. On January 15, 2026, the company’s management was scheduled to deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference, outlining its “string of pearls” portfolio approach, the advancement of its clinical and preclinical IRD assets, and its reliance on cost-effective programs, non-dilutive and voucher-related funding, and partnered strategic financial assets, framing a development model that could broaden its patient reach and potentially streamline regulatory and commercial paths for its gene therapy candidates.
The most recent analyst rating on (IRD) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Opus Genetics stock, see the IRD Stock Forecast page.
Spark’s Take on IRD Stock
According to Spark, TipRanks’ AI Analyst, IRD is a Neutral.
The score is held down primarily by weak financial performance (deep losses and significant cash burn), only partly offset by low leverage. Technicals are neutral with a modest longer-term uptrend but limited momentum. Recent corporate events are constructive (pipeline/regulatory progress and added funding/runway), while valuation remains challenged due to negative earnings and no dividend support.
To see Spark’s full report on IRD stock, click here.
More about Opus Genetics
Opus Genetics is a gene therapy company focused on developing adeno-associated virus (AAV) treatments for rare inherited retinal diseases (IRDs), pursuing a portfolio strategy that targets multiple IRD indications including LCA5, RHO, RDH12, CNGB1, NMNAT1, MERTK and BEST1, with two of its seven IRD assets already in clinical trials and an emphasis on cost-effective development, validated science and flexible regulatory pathways.
Average Trading Volume: 507,306
Technical Sentiment Signal: Buy
Current Market Cap: $137.9M
For an in-depth examination of IRD stock, go to TipRanks’ Overview page.